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Restoration of the antitumor activity ofp53 could offer a promising approach for the treatment of
neuroblastoma. MicroRNAs (miRNAs) are ünportant mediators ofp53 activity, but their role in the p53
response has not yet been comprehensively addressed in neuroblastoma. Therefore, we set out to
characterize alterations in miRNA expression that are induced by p53 activaüon m neuroblastoma cells.
Genome-wide miRNA expression analysis howed that nüR-34a-5p, miR-182-5p, miR-203a, miR-222-3p,
and miR-432-Sp are upregulated foUowing nutlin-3 treatment in a p53 dependent manner. The function of
miR-182-5p, miR-203a, miR-222-3p, and miR-432-Sp was analyzed by ectopic overexpression ofmiBNA
mimics. We observed that these p53-regulated miRNAs üihibit he proliferaüon ofneuroblastoma cells to
varying degrees, with the most profound growth inhibition recorded for miR-182-5p. Overexpression of
miR-182-5p romoted apoptosis in some neuroblastoma cell ines and induced neuronal differentiaüon f
NGP cells. Using Chromatin Immunoprecipitation-qPCR (ChIP-qPCR), we did not observe direct binding
ofp53 to MIR182, MIR203, MIR222, and MIR432 in neuroblastoma cells. Taken together, our findings yield
new msights in the network ofp53-regulated miRNAs m neuroblastoma.
nder normal physiological conditions, MDM2 inhibits p53 by bmding to its transcriptional activaüon
domain' and by promotmg its degradation via an ES-ubiquitin ligase activity2 maintaming low steady-
state levels of p53 expression. In response to various intrmsic or exü-msic stress signals, p53 is relieved
from MDM2 inhibition leading to acüvation of the p53-controlled program ofceü cyde arrest, cellular senescence
or apoptosis. The p53 transcripüon factor controls a transcriptional netwerk ofp53-responsive genes and non-
coding RNAs that coüectivdy drive a given ceUular response .. New insights mto the mechanisms by which p53
regulates ceUular growth/apoptosis/senescence an be gamed by identifymg up or downregulated microRNAs
(nuRNAs) upon p53 activation.
MiRNAs are smatl non-coding RNAs of 18-23 nucleoüdes m length that regulate gene expression at the post-
transcriptional level mainly by binding in a sequence specific manner to the 3'-untranslated regions (3'UTRs) of
messenger RNAs (mRNAs) and negatively regulating their expression2'4. MiRNAs have been shown to be an
integral component of the p53 pathway regulating multiple p53-controlled biological processes5. Altered express-
ion of tumor suppressive or oncogenic miRNAs can dismpt he p53-miRNA axis enhandng tumor growth or
decreasmg tumor proUfsration. Although several miRNAs such as the miR-34 famüy6, miR-1457, miR-1078, miR-
192, and miR-215" have been shown to be essential components of the p53 tumor suppressor network, the
spectrum ofp53 regulated miRNAs in neuroblastoma remains to be established m detaü.
Neuroblastoma is the most common extra-cranial solid chüdhood cancer. Although less than 2% ofneuro-
blastoma tumors diagnosed harbor a TP53 (p53) mutation, p53 fails to act as an efFective tumor suppressor10. In
consideration of the fact hat he paradigm of cancer treatment shifts from broadly acting enotoxic agents to
biologicaüy targeted therapies, the prospect oftargedngMDM2 to reactivate p53 holds promise for the molecular
therapy ofneuroblastoma. A small molecule antagonist ofMDM2, nutlin-3, can restore p53 function by selec-
tively disrupting the interaction between MDM2 and p53. Consequendy p53 accumulates and induces the
expression ofits target genes. We have previously shown that nuflin-3 has profound effects on neuroblastoma
cells and xenografts leadmg to premature senescence, apoptosis, and neuronal differentiation . .
In this study we performed a global megaplex profiling of 750 miKNAs in neuroblastoma cells after p53
activation and subsequendy identifled ifferentially expressed miRNAs. A neuroblastoma cell line lentivü-aUy
transduced with a shon haü-pin RNA against human p53 or murine p53 (negative control) was used to identify
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Figure l | Nuüin-3 induces p53-regulated miRNAs and genes. (A), NGP cells were fa-eated with O or 16 |iM nudin-3 for 24 hours. Expression fold
changes of 750 miRNAs was determined using megaplex stem-loop RT prmiers and nuKNA RT-qPCR. The scatter plot represents the average fold change
expression values of expressed miKNAs in NGP cells after nutlin-3 treatment. miRNAs that demonstrated a Imear fold change larger than 2 (>2-fold
upregulation) or lower than 0.5 (<2-fold ownreguladon) were considered for further analysis. miR-222-3p, miR-34a-5p, miR-182-5p, miR-432,
and miR-203a weie upregulated and no miRNA was found to be downregulated. (B), p53 target genes are selectively induced in the control cells upon
nutlin-3 treatment. NGP-LV-hp53 (kd) and NGP-LV-mp53 (wt) ceüs were treated with O or 16 |iM nutlin-3 for 24 hours with the ethanol (solvent)
concentration kept constant. Results are RT-qPCR normalized relative mRNA expression values (linear scale, mean of 2 reactions ± SEM) for direct p53
target genes; CDKNlA(p21), MDM2, BBC3 (PUMA), TNFRSF10B, and TP53I3. (C), NGP-LV-hp53 (kd) and NGP-LV-mp53 (wt) ceUs were treated with
O or 16 pM nudin-3 for 24 hours. Relative expression ofmiR-34a-5p, miR-222-3p, miR-432-5p, müt.-182-5p, and miR-203awas determined bymiRNA
TaqMan assays in a multiplex primer pool. Data represents the average relative miRNA expression ofthree independent biological replicates (linear scale,
mean ± SEM, one-tailed Student Mest: *P < 0.05, **P < 0.001). miR-500. miR-503, and miR-484 were the most stable miRNAs from the megaplex
profiling and were used as mtemal controls in the multiplex pool for normalization purposes. Dotted line represents the 2-fold threshold. (D), NGP ceUs
treated with O or 16 |lM nudin-3 for 24 hours. Expression ofpri-miR-34a, pri-miR-222, pri-miR-432, pri-miR-182, and pri-miR-203 was determined
using primary miRNA TaqMan assays.
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Figure 2 | Overexpression ofmiRNAs reduces proliferation of neuroblastoma celk. Neuroblastoma cell lines were transfected with the indicated pre-
miRs, and their growth was assessed using the xCELUgence system. The data shown represents the percentage ofcell viability of the neuroblastoma
ceU Unes 96 hours post transfection with the indicated pre-miRs. Two-taüed paired t-test was used to compare the viabüity of the neuroblastoma cell Unes
transfected with the pre-miRs to the negative control *q (corrected p-value) < 0.05, ** q < 0.001). IMR-32 (A), SK-N-AS (B), NGP (C), SK-N-BE(2c)
(D), N206 (E). Protein expression offull ength PARP (upper band) and deaved PARP (lower band) in SK-N-BE(2c) cells 48 hours post transfection with
pre-nuR-222-3p or pre-miR-NC (non-targeting control). P-actin was used as a loadmg control (F).
the p53-dependent ature of the miRNA expression alterations. We
report here that four miKNAs (miR-222-3p, nuR-432-5p, miR-182-
5p, and miR-203a) are upregulated after p53 activation mneuroblas-
toma cells. Using the xCELLigence Real Time CeU Analyzer (RTCA)
we demonstrate that overexpression of these nuKNAs inhibits
neuroblastoma cell growth to varying degrees as compared to neu-
roblastoma ceUs transfected with scrambled pre-miR. MiR-182-5p
displayed the strongest growth-suppressive activity, had pro-apop-
totic activity in some neuroblastoma cell ines and induced neuronal
differentiation fNGP ceUs.
Results
Nutlin-3 induces p53 regulated miRNAs and p53 responsive
genes. The p53 protein is known to activate the transcription of a
subset ofmiRNA-coding genes1'3'5; however, litde is known about the
p53-regulated miKNAs in neuroblastoma. To identify p53-regulated
nuRNAs in neuroblastoma cells we treated the human p53 wild-type
neuroblastoma ceU line NGP with O or 16 |iM nudin-3 for 24 hours
with two independent biological replicates. Subsequently, we
performed a whole genome miRNA expression profiling using
TaqMan based miRNA expression platfonn, and calculated the
average miRNAs expression fold changes between treated and
untreated cells with +/- 2X as a linear fold change cut-offvalue.
Our results confü-m that miR-34a-5p is upregulated after nudin-3
treatment (figure IA) in line with what is reported about mir-34a-5p
as a direct arget ofp532A5. Besides miR-34a-5p upregulation, miR-
222-3p, miR-182-5p, miR-203a and miR-432-5p are upregulated as
weU. No miRNAs were found to be downregulated by crossing
the 0.5 fold change. To assess whether the upregulation of the
aforementioned nüRNAs is specificaüy mediated by p53, we used
NGP cells lentivirally transfected with a short hairpin RNA against
human TP53 (NGP-LV-hp53) or murine TP53 (NGP-LV-mp53)5'".
The ceUs were treated in the same way by O or 16 tiM nutlin-3 for
24 hours. The model system was first validated by analyzing the
expression of 6 direct p53 target genes using RT-qPCR (figure 1B).
The basal expression of these genes was Mgher and increased further
upon nutlm-3 treatment in NGP-LV-mp53 ceUs (control) as
compared to the NGP-LV-hp53 cells (p53-knock down).
Next we confirmed the upregulaüon of these selected miRNAs by
multiplex RT-qPCR (figure IC). In general, the basal expression of
the miRNAs was higher and increased upon nuüm-3 treatment m
the control ceUs as compared to the NGP-LV-hp53 cells (p53-KD).
MiR-222-3p was found to be upregulated by more than 8-fold in
response to nutUn-3 treatment, whereas miR-34a-5p showed 4-fold
upregulation, MiR-432-5p, miR-203a, and miR-182-5p showed 2-
fold upregulation (figure IC).
p53 has been shown to enhance the processing of precursor
miRNAs5. We measured the expression of the precursor nuKNAs
using TaqMan based assays. Oiir results show that the expression of
the precursor miRNAs has a sünilar pattem to the expression of the
mature miRNAs, suggesting that he regulation of these miRNAs is at
the transcriptional level (figure 1D).
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Figure 3 [ miR-182-Sp induces neurite outgrowth in NGP cells. NGP cells were transfected with pre-miR NC (A,C), or pre-miR-182-5p (B,D).
Neurofilament staimng was done 5 days post transfection. The upper panel (A,B) shows the morphology ofcdls before stammg, Nudei were stained with
blue fluorescent DAPI, and red fluorescence for neurofilaments with Cy3 anti-neurofilament antibody (C, D). Box plots showing the length of the neurites
in tun, the horizontal ine represents the median, the box represents the interquartile range, the whiskers represent 10-90 percentile, and the dots
represent he outliers (E).
OUT results show that miR-222-3p, miR-182-5p, miR-203a and
miR-432-5p are upregulated m neuroblastoma ceU lüies after p53
activation by nuüm-3.
nuR-182-Sp inhibits the proliferation ofneuroblastoma cells. To gain
insight into the effect of ectopic overexpression of miR-222-3p,
miR-203a, miR-182-5p, and miR-432-5p on the proliferaüon of
neuroblastoma celk, we transfected 5 ceU lines with pre-miRs
(miRNA mimics) and evaluated the cell growth m real time using the
xCELUgence system. Twop53-wüd type (NGP and IMR-32) and tfaree
^53-mutant (SK-N-BE(2c), N206, and SIOSTAS) neuroblastoma ceU
lines were used. The ceUs were seeded m duplicates and transfected
vrith 100 nM of scrambled pre-rmR serving as a. negative miRNA
control (pre-nuR-NC), or pre-miR precursor molecule for nuR-222-
3p, miR-203a, miR-182-5p, and iruR-432-5p. MiR-182-5p shows the
most promment mhibition of the proUferaüon of neuroblastoma cells
(figure 2A-2E). The real time viability data of the teanfection with the
four nuRNA mmiics is shown in figure SI. Furthermore, miR-182-5p
showed pro-apoptotic activity, as demonstrated by its ability to induce
PARP cleavage in SK-N-BE(2c) cells and to a lesser extent also m SK-N-
AS and N206 cells (figure 2F).
In short, our results how that overexpression f the p53-regulated
miRNAs inhibit he proliferation ofneuroblastoma ceUs to varying
degrees. In addiüon, overexpression of miR-182-5p can promote
apoptosis, as demonstrated by PARP cleavage.
miR-182-5p upregulaüon induces differentiation of NGP cdls. We
previously reported that nudin-3 treatment may induce dtfferentiation
of certam neuroblastoma ceüs' and thus hypothesized that p53 upre-
gulated miRNAs can act as positive mediators of this differendation
response. To eluddate the effect of ectopic overexpression of the four
nnKNAs on cellular difierentiation, we performed neurofilament
stainmg 5 days post pre-nuR transfection in NGP celk In short,
NGP ceUs ware transfected with mature microRNA mümcs or a
negative control. Overexpression of nuR-182-5p clearly induced
neuhte outgrowth 5 days post bansfection (figure 3). The other
nuRNAs did not induce neuroblastoma differentiation.
p53 does not bind to MIR182, MIR203, MIR222, and MIR432 m
neuroblastoma ceUs. In an attempt to characterize the mechanism of
the p53 regulation of miRNAs, we used publicly avaüable TP53
chromatm immunoprecipitation - sequencing (ChIP-Seq) data
from IMR-90 normal lung fibroblast cetls and Saos-2 osteosarcoma
ceUs (GEO GSM783262 and GSM501692, respectively). We also
used preprocessed data of chromatin marks for osteoblasts. The
data was used to identify potential binding sites of p53 in the
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Figure 41 p53 ChIP-Seq and ChIP-qPCR. IGV visualization ofMACS ChIP peak results using p53 ChIP-Seq data fi-om normal lang fibroblast cells (IMR-
90; upper part) and osteosarcoma cells (Saos2; lower part). Chromosome X is shown at the top of the figure with a red marker representing the
location ofmiR-222-3p at Xpl 1.3. From top to bottom: peaks identified by MACS represent the pfleup signal of the input (pre-OiIP) sample after mapping
the reads to the sequence in the top of the figure. The input sample track shows non-specific background. The next rack represents the peaks of the mapped
reads using p53 antibody (p53 ChIP-Seq) after subtracting the non-specific background signal of the input sample. The lower part represents the signal from
H3K4me3 data that marks the start of active transcription; and the signal from H3K36me3 data that marks the transcription elongation (A). ChIP-qPCR
perfomied on p53-CMP material from MYCN3, a p53-wïd type neuroblastoma ceü line. CDKN1A is a positive control p53 target gene (B).
transcripüon start site of the miRNAs upregulated upon p53
activation. Usmg Model-based Analysis of ChIP-Seq (MACS)8'12
we identified enriched regions of p53 bindmg sites in the
transcription start sites of MIR222 (figure 4A). These data suggest
that MIR222 could be a direct arget ofp53, at least in these sample
types. However, qPCR on p53-ChIP material from a neuroblastoma
cell ine with wüd-type p53 (MYCN3) treated with nuüin-3 could not
confirm direct bindüig of p53 to MIR182, MIR203, MIR222, and
MIR432, whereas p53 binding to a positive control p53 target gene
(.CDKN1A) was clearly shown (figure 4B). In short, p53 appears to
induce the expression of these miRNAs indü'ecüy and not through
direct bmdüig to their promoter region.
Discussion
MiRNAs are well known to be differentially expressed m tumors as
compared to normal tissues9'". Characterizmg this differential
expression may help us to understand better how tumors evade the
apoptotic machmery, and proceed through the cell cycle and conse-
quendy cell growth and survival. As a guardian of the genome, p53
represents a central node that controls the dedsions ofeither execut-
ing the apoptosis program or mducing survival and proliferation ' .
In consideration of the fact that less than 2% of neuroblastoma
tumors harbor a mutation in TP53 at diagnosis10, it becomes reas-
onable to probe the p53 pathway and identify the factors that assist
neuroblastoma tumors to sustain their growth potential and evade
p53 pathway suppressmg effects. Expression changes m 15% ofp53
pathway genes after p53 activation in response to stress signals is
attributable to miRNAs5. In this study, we identify p53-regulated
imRNAs via global expression profiling of 750 miRNAs in the
MÜAG-amplified neuroblastoma NGP cells after nuüin-3 treatment.
Using NGP ceUs lentivü-aUy transfected with a short hairpin RNA
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against human TP53 (NGP-LV-hp53) or murme TP53 (NGP-LV-
mp53), we were able to confirm and validate the upregulation four
miRNAs (miR-222-3p, miR-432-5p, miR-203a, and miR-182-5p) by
p53 m neuroblastoma cells. We applied a strict selection criterion
and excluded all miRNAs that had less than 2-fold differential
expression. In addition to these four upregulated miRNAs, miR-
34a-5p was also found to be upregulated. MIR34A is located at
lp36, a frequendy deleted region in neuroblastoma tumors and has
been characterized as a tumor suppressor gene in neuroblastoma
tumors15. In addition, MIR34A has already been reported to be a
direct arget ofp536. As miR-34a-5p has already been studied exten-
sively m Uterature, we did not focus in our fiuictional analysis on this
miRNA. Nevertheless, observed upregulation of miR-34a-3p and
miR-34a-5p in NGP ceUs after p53 activation is a nice positive
control.
We invesügated the functional effects of miR-222-3p, miR-432-
5p, miR-203a, and miR-182-5p m ^53-wüd type and p53-m\üaiit
neuroblastoma cell Imes. Our results showed that ectopic overex-
pression of these miRNAs using nüKNA minücs reduced the growth
of the neuroblastoma cell ünes, with the most pronounced effects
being induced by miR-182-5p. Pro-apoptotic activityofmiR-182-5p
was documented by demonstrating its abüity to mduce PARP cleav-
age in SK-N-BE(2c) cells and to a lesser extent also in SK-N-AS and
N206 ceUs.
In addition, miR-182-5p induced neuronal differentiation fNGP
ceUs. MiR-182-5p has already been shown to be upregulated after p53
activation in several cancer entides such as colon cancer", lung can-
eer16, and uveal melanoma1 . In addition, p53 has been reported to
enhance the post-transcriptional maturation ofmiR- 182-5p . These
data support our findmgs on the regulation ofmiR-182-5p by p53.
Ofnote, miR-182-5p has been reported to mhibit he growth of
melanoma cell lines" and the proliferation of gastric adenocard-
noma cell lines20. However, miR-182-5p was also reported to be a
potent anti-apoptotic miRNA in colon cancer2
1 and m hepatocellular
carcmoma2, suggestmg a tissue-specific effect.
It is worth mentioning that he other p53-regulated miKNAs have
also akeady been implicated in cancer. For example, miR-222-3p
functions as an oncogene in some tumors and as a tumor suppressor
in others10'23'24, which also suggests that the function ofmiR-222-3p
is tumor and cellular context dependent.
MIR203 and MIR432 are located at 14q32.33 and 14q32.31
respectively, a frequendy deleted region in neuroblastoma tumors23.
Upregulation ofmiR-203awas hown to be dependent on p53 activa-
tion in keratinocytes25, and p53 was also reported to enhance the
post-transcriptional maturation of miR-203a18, and it has been
described intensively as a tumor suppressor m several cancer
entities26-28.
LitÜe mformaüon exists about nuR-432-5p in literature. This
miRNA has been reported to play atumor suppressive role in pituitary
adenocardnoma and to be higMy upregidated uring senescence of
fibroblasts30 and during the earliest stages offetal development31. We
analysed the expression ofmiR-432-5p in neuroblasts and neuroblas-
toma samples. We found that miR-432-5p expression is assodated
with progression free survival ofneuroblastoma patients and that this
miRNA is expressed at higher levels m neuroblasts as compared to
neuroblastoma tumors (figure S2).
Conclusion
We have identified four p53-regulated miRNAs, which mhibit he
growth of neuroblastoma cells. The most profound inhibition of
proliferation was observed for miR- 182-5p, which was shown to have
pro-apoptotic acüvity in some neuroblastoma cell Unes and to induce
neuronal differentiation f NGP ceUs. Further esearch is Ukely to
add more miRNAs to the growing list ofp53-regulated miRNAs, and
fiuther functional assays are required to dedpher the molecular
mechanisms underlying the p53-mediated cellular esponses.
Methods
Cell lines and nutlin-3 treatment Human neuroblastoma cell ines used m this study
are: NGP, NGP-lv-hp53, NGP-lv-mp53, SK-N-AS, SK-N-Be(2c), IMR-32, MR-32-
lv-hp53, IMR-32-lv-mp53. NGP/IMR-lv-hp53 and NGP/IMR-lv-mp53 are ceU Imes
lentivirally transfected with a short hairpin RNA against human p53 or murine p53
(control), respectively . Cells are grown as monolayer cultures at 37 C and 5% Cö^ in
a humid aünosphere. The culture medium is complete RPMI 1640 (GIBCO, Life
Technologies) containing 10% Foetal Calf Serum (FCS), and the followlng anübiotics
unless stated otherwise: Pemcillin (1%), KAnamydn (1%), Streptomycm (1%) and
2 mmoVl glutamine. Nutlin-3 (Cayman Chemical) was dissolved m ethanol and
stored as a 10 mM stock solution at -20°C. Keeping the final concentration of
ethanol constant, cells were treated with Dudia-3 ranging from O to 16 pM for the
time periods indicated. Calculation of the volumes needed for the nutlin-3 treatment
was done usmg the online calculaton www.calculators.alirihatu.com.
RNA extrartion. Cells were harvested by scraping and total RNA was extracted using
miRNeasy Micro Kit (Qiagen, Hildm) with RNase-free DNase I treatment performed
on RNA extraction spin column according to the manufacturer's instructions. RNA
concentration was measured using the Nanodrop UV spectrophotometry platfonn
(Nanodrop Technologies, USA). RNA mtegrity for all samples was assessed using
Eïcperion (software version 3.2, Bio-Rad).
Megaplex/mulüplex miRNA reverse transcripüon, pre-ampUfication and
expression quantification. Reverse transcription of 750 miRNAs was done using
reverse transcripüon kit (Applied Biosystems) and stem-Ioop Megaplex primer pools
(Applied Biosystems). In short, 80 ^ dreaction volume was preparedbyaddmg 8 plof
total RNA (50 ng/pl), RT primer mix (10X), RT buffer (10X), Mulüscribe Reverse
Transcriptase (10 U/pl), dNTPs with dTTP (0.5 mM each), MgCk (3 mM) and AB
KNase mhibitor (0.25 U/ml). A plllsed RT reaction was then performed with 40
cycks of l6°C for 2 min, 42°C for l min, and 50°C for l s. These 40 cycles were
followed by increasmg the temperature to 85°C for 5 mmutes to inactivate the reverse
transcriptase. Afterwards, the RT product was pre-amplified ma 25 [d FCR reacüon
using Applied Biosystems' TaqMan PreAmp Master Mix (2X) and PreAmp primer
mb[ (5X), The primerpool consisted of a universal reverse primer (50 nM) (Applied
Biosystems) and 750 forward primers (50 nM) spedfic for each nuRNA. The
foüowing pre-ampüfication cyclmg condiüons were used: 95°C for 10 min, 55 C for
2 min,and75°Cfor2 minfollowedbyl4cyclesof95°Cfor 15 sand60°Cfor4 min.
Real-time qPCR was performed using the 7900HT RT-qPCR system (Applled
Biosystems) in 8 pi reacüon consistüig of 4 ^  of TaqMan Master Mix (Applied
Biosystems), l |ll ofcDNA, and 3 yl ofmiRNA TaqMan probe and primers (Applied
Biosystems). The followmg cyding conditions were applied: 95°C for 10 mm
foUowed by 40 qrcles of 95°C for 15 s and 6Q°C for l min. Raw Cq values were
determined using SDS 2.1 software with automated baseline settings and 0.2 treshold
value (see Ref. 32 for more details). Only miRNAs with Cq values of 32. or below were
amsidered for fiirther analysls. The rdaüve xpression ofmiRNAs was nonnaUzed
using mean expression values of all expressed nüRNAs m every sample according to
Mestdagh et al".
To vaüdate the megaplex miRNA profiUng results; we perfbrmed multiplex by
followüig the same protocol described above with slight modifications. Briefly RNA
was reverse transcribed using multiplex RT primer pools contammg mIRNA-speciflc
stem-loop rimers for the miRNAs in quesüon. No pre-ampliScaüon was done, and
the total volume ofRT-qPCR reaction was 5 ld. Normalization was done in qbase+
using the geometrie mean expression value of the most stably expressed miRNAs
identified after the megapkx profiling. Measuring the miSNAs precursors was doae
using stem-loop TaqMan assays. The cDNA was prepared using the high capacity RT
kit(AppliedBiosystems) addingSO ng of total RNA,RTbuffer(2X),RTenzyme mix
(20X) and RNase-frêe water to a reaction volume of 20 ^ . A pulsed RT reaction was
then performed as described above. qPCR was then performed accordmg to the
manufacturer's protocol usülg 10 ng of the RT product, TaqMan universal master
mix (2 X) and TaqMan Pri-miRNA assays (20 X) (AppUed Biosystems) in 8 4]
reaction volume. The following cyding conditions were applied: 95°C for 10 mm
followedby40cydesof95°Cforl5 sand60°Cforl min.
Pre-miR transfecüon. Neuroblastoma cells were transfected with individua] pre-nüR
mokcuks (Ambion) at a concentration f 100 nM using DharmaFECT 2transfecüon
reagent (Thermo Scientific). Pre-miR negative control 2 (Ambion) was used as a
scrambled control. Cellwere seeded in RPMI (Invitrogen) with 10% FCS and without
antibiotics.
Cell growth assessment. xCELLigence MP device from Roche Diagnostics was used
to monitor cell proliferaüon in real-time. This system measures electrical impedance
on the bottom of tissue culture lectronic microtiter plates (E-Phte; Roche
Dlagnostics). The signal from the interdigitated lectrodes at the bottom ofevery weU
Is measured as the cell index. Prior to seedüig, bad^round impedance was
determmed using 40 pi of media (RPMI) contaüüng 10% FCS and always ubtracted
as blank value. l X 10-' cdls in 50 pi ofRPMI containing 10% FCS were seeded in
duplicates. The experiment was repeated three times. Cell proliferation was measured
with a programmed signal detection every 15 mm and the signal was normalized to
the transfecüon time point where the cell index at eveiy time point was divided by the
ceU index at the time of transfecüon. Data acquisition and analysis was performed
with the RTCA software (version 1.2, Roche Diagnostics).
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RT-qPCR. Relaüve expression ofprotem coding genes was performed by RT-qPCR
according to MIQE guidlines'4. Briefly, cDNA synthesis was performed on the
isolated RNA using iScript cDNA synthesis kit (Bio-Rad) according to the
manufacturer's mstructions.
RT-qPCR was done in duplicates in 5 |il reaction volume contammg 2 |il (5 ng) of
template cDNA, 2.5 pi of2X Sso Advanced reaction mu (Bio-Rad), 0.25 pi of a
5 \ïM soluüon ofeach primer. LightCycler 480 (Roche) was used with the following
cycling conditions: 10 s at 95°C followed by 45 cydes of denaturation (10 s at 95°C)
and dongation (45 s at 60°C). Primers were designed using RTPrimerDB35.
Biogazelle s qbase+ qPCR data-analysis oftware36 was used to quantify the relative
expression ofgenes Chttp://www.qbaseplus.com). Most stably expressed reference
genes selerted from a panel of 10 commonly used reference genes were used for
nonnalizaüon. Primer sequences are avaflable in the RTPrimerDB database (http://
www.rtprimerdb.org): ACTB (RTPrimerDB ID #1), B2M (#2), GAPDH (f3), HMBS
(»4), HPRT1 (#5), RPL13A (#6), SDHA (#7), UBC(#8), YWHAZ (#9). The sequence
of the Alu repeats primers are CATGGTGAAACCCCGTCTCTA for the forward
primer and GCCTCAGCCTCCCGAGTAG for the reverse primer.
Western Mot. CeUs transfected with pre-miR-222 or pre-miR-NC for 48 hours were
harvested and washed using ice cold PBS, centrifüged and the supeinatant discarded.
The pellet was solubilized in MPA lysis buffer (Pierce) contaüung protease and
phosphatase mhibitor mbiture (Roche). Cell lysates were placed on ice for 30 mimites
and centrifüged for 10 minutes at 12,000 rpm at 4°C. The protein concentraüon was
measured using the Bio-Rad Protein Assay (Bio-Rad). Protein samples were mixed at
l: l ratio with Laemmli denaturation buffer (Bio-Rad) and P-mercaptoethanol
(Sigma Aldrich) at a final dilution of 1/40 and boiled for 10 minutes at 95°C.
Approximately 25 |jg ofprotein was loaded and fractionated using a 10% SDS-PAGE
gel (Bio-Rad). The protein was transferred onto a nitrocellulose membrane (Bio-Rad)
and immunoblotted with antibodies against deaved PARP (Cdl Signaling
Technology) and P-actüi (Sigma Aldrich.) as a loadmg control, Secondary antibody
was anü-mouse HRP-Imked (Cdl Signalmg Technology). Visualizaüon of the
proteins was done using the ChemiDoc-Jt Imaging System (UVP).
In Vitro Differentiation assay. Immunocytochemistry was performed to detect
differeatiaüon ofNGP cells. Briefly, 10S NGP cells in 1.9 mi ofcell suspension with
10% FCS and without antibiotics were seeded in 6-weU plates contamüig heat
sterilized drcular coverslips. 24 houis later, the cells were transfected as described
above, and kept m an incubator at 37°C. After 4 days the 6-well plates were placed on
ice for 30 min, and Uien culture medium was aspirated from each wdl and the cells
vieze imsed. gendy in phosphate buffered saline (PBS) (Invitrogen). The cells were
then fixed by incnbating them for 20 min in l mi PBS (pH = 7.4) containing-
paraformaldehyde (3.7%) and subsequendy incubated in l mi NH4C1 (50 mM) for
10 min on ice. Fixed cells were washed with PBS and permeabüized with ice cold
acetone for 10 min. Thereafter, penneabüized ceÜs were washed with PBS and
blocked by incubating them on ice for 20 min in l mi PBS containing Fish Skin
Gelatm (0.2%). The cells were then incubated with undiluted mouse monodonal anti-
neurofllament (NE-14) anübody (BioGenex) for l hour at room temperature.
FoUowing, the cells were washed with PBS and incubated with Cyanine 3 (Cy3)-
conjugated secondary anti-mouse antibody for l hour at room temperature. CeUs
were Uien washed wiüi PBS and transferred onto a sHde. A droplet of4,6-diamidino-
2-phenylindole (DAPI) was added to stain the nuclei. The cells were finally visuali2ed
using Zeiss Axioplan 2 ünagmg analysis system (Carl Zeiss) equipped with an HBO-
100 WHgvaporlamp,63.0 X l.25 oil-immersionobjective and appropriate filter sets
for DAPI and Cy3 dyes. The images were captured by a digital camera (IAI
corporation) and analyzed by Isis FISH Imaging System software VS. l (MetaSystems
GmbH).
CUP-Seq data analysis. Raw p53 ChIP-Seq data was downloaded from Gene
Expression Omnibus (GEO)-GSM783262 (normal ung fibroblasts-IMR-90) and
GSM501692 (osteosarcoma-Saos-2). Reads from the raw data were aligned using
Burrows-Wheeler Aügnment ooi (BWA) , and the peaks were called using MACS
software12. ChIP tracks showmg p53 binding sites were visualized usmg Integrative
Genomics Viewer (IGV)'8.
CUP qPCR. ChIP was performed on l X 10' MYCN3 neuroblastoma cells eifher
ü-eated or untreated with nudin3a for 8 h usmg ChIP-IT Express Chromatin
Immunopredpitation Kit (Active Motif) accordmg to manufacturer's mstrucüons.
Samples were sonicated for 20 cycles of 30 sec intervals m a Bioruptor UCD-200
sonicator (Diagenode). CHIP was performed with Negative control Ab (control IgG)
and anü-human p53 andbody and au the samples were validated by performmg
CMP-qPCR using spedfic primers ofp53 binding site at p21 promoter -2 kb site
(EpiTect Chip ChIP-Grade Antibody Kit (p53), SABiosdences). Input was generated
by punfyüig DNA from the sonicated lysates of each sample.
The identification of the miRNAs transcription start site (TSS) was based on a
study by Ozsolak et al.3'. The ChIP-qPCR primers listed in table SI were designed
using -Primer 3"° and were validated for specifidty using Bowüe as an alignment
tooi41, and the SNPs were iiltered out using the dbSNP database". RT-qPCR was
performed as described above using 4 ng of the eluted DNA material. Dissodation
curves were analyzed for each primer pair as a means to ensure the quality of
amplicon and to momtor primer dimers. The ChIP-qPCR data was analyzed
accordmg to the fold enrichment method where the data was normalized to mulüple
non-spectfic genomic regions (not bound by p53) and analyzed relative to an input
sample. .
Staüsücal methods. For the survival analysis, paüents were divided into four
quartiles accordmg to the expression status ofmiR-432 m their neuroblastoma tumor
(low expression to high expression). Comparison ofKapIan-Meier survival curves
between different groups was done usmg the log-rank test. ^ -values < 0.05 were
considered statistically significant. AU statistical analyses were conducted using R
version 3.0.2 using "stats" staüsücal package.
Comparison of the length of the neurites between NGP ceUs transfected wifh pre-
miR-182-Sp and NGP cells transfected with negative control was done using the
unpaired t-test in SPSS veision 20 software.
Two-taüed paired t-test was used to compare the yiability of the neuroblastoma cell
lines transfected with the pie-miRs to the negative control. The test was done in SPSS
version 20 software on the data oftwo biological replicates (two experiments with two
replicates per conditkm). This analysis was followed by Benjamüü-Hochberg mul-
tipk testing correction in Rversion 3.0.2 using "stats" statistical package. Resultswith
corrected ^ -values (g-values) < 0.05 were considered statisticaUy significant,
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